Autres langues AnaptysBio, Inc.

Actions

ANAB

US0327241065

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 25/04/2024			Varia. 5j.	Varia. 1 janv.
18,87 ^USD	-2,08 %		-4,84 %	-11,90 %

16/04	ANAPTYSBIO, INC. : Leerink Partners optimiste sur le dossier	ZM
11/04	ANAPTYSBIO, INC. : Wells Fargo Securities maintient sa recommandation à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

AnaptysBio, Inc.(NasdaqGS:ANAB) added to S&P Biotechnology Select Industry Index	18/03
North American Morning Briefing : Stock Futures -2-	13/03
AnaptysBio Shares Jump on Upgrade by Wedbush	12/03
AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11/03
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	11/03
AnaptysBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	11/03
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting	29/02
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting	29/02
AnaptysBio Shares Climb as Piper Sandler Starts Coverage With Overweight Rating	16/02
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference	31/01
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference	31/01
AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from S&P Biotechnology Select Industry Index	18/12
GSK : l'UE approuve Jemperli dans le cancer de l'endomètre	11/12
AnaptysBio Secures Exclusive License for Centessa's BDCA2 Modulator Antibody Portfolio	27/11
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals	27/11
Anaptys Named a BioSpace 2024 Best Places to Work Winner	07/11
Anaptys Named a BioSpace 2024 Best Places to Work Winner	07/11
Acne Vulgaris Pipeline\| Clinical Trials, Key Companies - Novan, Bausch Health AOBiome, Ascletis Pharmaceuticals, AnaptysBio, Botanix Pharmaceuticals	07/11
AnaptysBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update	02/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues AnaptysBio, Inc.

Actions

ANAB

US0327241065

Autres langues

Filtres